Mesdopetam hemitartrate
Modify Date: 2024-01-15 09:20:07
Mesdopetam hemitartrate structure
|
Common Name | Mesdopetam hemitartrate | ||
|---|---|---|---|---|
| CAS Number | 2562346-14-7 | Molecular Weight | 700.77 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C12H18FNO3S.1/2C4H6O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Mesdopetam hemitartrateMesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease[1][2]. |
| Name | Mesdopetam hemitartrate |
|---|
| Description | Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Mesdopetam (IRL790) (3.7, 11, 33, or 100 µmol/kg; s.c.) hemitartrate dose-dependently inhibits the behavioral activation following pretreatment with D-amphetamine or MK-80[1]. Mesdopetam (10 mg/kg; intraperitoneally; fourteen-week-old male C57BL/J mice) hemitartrate promotes a sedative effect similar to haloperidol with significantly reduced total distance traveled and reduced average speed[2]. Animal Model: Male Sprague-Dawley rats[1] Dosage: 3.7, 11, 33, or 100 µmol/kg (synthesized in-house as HCl salt, was dissolved in physiologic saline (0.9% w/v NaCl) Administration: s.c. was administered subcutaneously 4 min before the start of recording Result: Dose-dependently inhibited the behavioral activation following pretreatment with D-amphetamine or MK-801. |
| References |
| Molecular Formula | C12H18FNO3S.1/2C4H6O6 |
|---|---|
| Molecular Weight | 700.77 |